
    
      Treatment with ixabepilone will be given at an assigned dose as a 3 hour intravenous infusion
      on day 1 of a 21 day cycle. Treatment with pazopanib will be given at an assigned dose by
      mouth once a day, beginning on day 1 and continuing daily. Disease assessment will be done
      every 2 cycles (6 weeks) with treatment continuing until disease progression, unacceptable
      toxicity or patient refusal.
    
  